 | |
| Clinical data | |
|---|---|
| Trade names | Savaysa, Lixiana, Roteas, others |
| Other names | DU-176b |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614055 |
| License data | |
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 62%; Tmax 1–2 hours[4] |
| Protein binding | 55%[4] |
| Metabolism | minimal CES1, CYP3A4/5, hydrolysis, glucuronidation[4] |
| Elimination half-life | 10–14 hours[4] |
| Excretion | 62% feces, 35% urine (97% of 60 mg)[4] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C24H30ClN7O4S |
| Molar mass | 548.06 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Edoxaban, sold under the brand-name Lixiana among others, is a anticoagulant (blood thinner) used to prevent and treat blood clots.[6] It is not clear if it is safe with prosthetic heart valves.[6] It is taken by mouth once a day; either 30mg or 60mg depending on body weight and kidney function.[6]
Common side effects include nose bleeds, blood in the urine, and anemia.[7] Other side effects may include nausea, skin rash, and brain bleeding.[6] Compared with warfarin it has fewer interactions.[4] It is in the direct factor Xa inhibitors family of medications.[6]
Edoxaban was developed by Daiichi Sankyo and approved for medical use in Japan in 2011.[8] Approval in the United States and Europe occurred in 2015.[9][7] In the UK, a month supply costs the NHS around £50 as of 2021, more than 50 times that of warfarin, although this difference may be offset by lower monitoring costs.[6][10] This amount in the United States costs about 390USD.[11]
References edit
- ^ "Savaysa- edoxaban tosylate tablet, film coated". DailyMed. 24 April 2020. Archived from the original on 23 July 2020. Retrieved 23 July 2020.
- ^ "Lixiana EPAR". European Medicines Agency (EMA). Archived from the original on 24 October 2020. Retrieved 23 July 2020.
- ^ "Roteas EPAR". European Medicines Agency (EMA). Archived from the original on 25 November 2020. Retrieved 25 September 2020.
- ^ a b c d e f Parasrampuria DA, Truitt KE (June 2016). "Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting FactorXa". Clinical Pharmacokinetics. 55 (6): 641–55. doi:10.1007/s40262-015-0342-7. PMC 4875962. PMID 26620048.
- ^ "Edoxaban (Savaysa) Use During Pregnancy". Drugs.com. 17 June 2020. Archived from the original on 18 May 2021. Retrieved 18 May 2021.
- ^ a b c d e f BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 135-136. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ a b "Lixiana 60mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Archived from the original on 5 March 2021. Retrieved 18 May 2021.
- ^ "First market approval in Japan for Lixiana (Edoxaban)". Daiichi Sankyo Europe GmbH (Press release). 2011-04-22. Archived from the original on 2013-11-06.
- ^ "Edoxaban Tosylate Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 14 July 2021.
- ^ Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (2nd ed.). Elsevier. pp. 118–119. ISBN 978-0-7020-7442-4. Archived from the original on 2021-05-22. Retrieved 2021-11-09.
- ^ "Edoxaban Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 July 2021.